DUBLIN – Immatics NV is banking $150 million up front and could earn up to $770 million more in development, regulatory and commercial milestones from a licensing deal with Bristol Myers Squibb Co. involving IMA-401, its lead bispecific engineered T-cell receptor (TCR).
Regor Therapeutics Group and Eli Lilly and Co. have inked a collaboration and licensing deal to co-develop therapies for metabolic disorders in a deal worth more than $1.5 billion. Under terms of the agreement, Lilly is gaining access to Regor IP to support its development of therapies for obesity and diabetes.
Ildong Pharmaceutical Co. Ltd. inked a partnership with Shionogi & Co. Ltd. to co-develop S-217622, the latter’s orally administered 3CL protease inhibitor treating COVID-19 and has obtained an IND for a phase II/III trial in South Korea to enroll more than 200 patients who are asymptomatic or suffering from mild to moderate COVID-19.
Bright Peak Therapeutics Inc. has licensed rights to use Livzon Mabpharm Inc.’s anti-PD-1 candidate, LZM-009, to develop its own PD-1 targeted immunocytokines (PD-1 ICs). Bertolt Kreft, chief scientific officer for Bright Peak, told BioWorld that Livzon’s phase II anti-PD-1 “exhibits a promising initial safety and efficacy profile, making it well-suited to the task.
Acelyrin Inc. closed a $250 million series B round and, at the same time, unveiled a licensing deal with Affibody AB, involving an interleukin-17A (IL-17A) inhibitor, izokibep, which it is now testing in a pivotal trial in uveitis. Solna, Sweden-based Affibody is getting $25 million up front and could earn up to $280 million more in regulatory and sales-based milestones, as well as tiered royalties, ranging from high single digits to low double digits in percentage terms.
Shares of Alkermes plc slipped 15% Nov. 9 on news that longtime partner Janssen Pharmaceutica NV plans to partially terminate two license agreements related to know-how royalties on U.S. sales of paliperidone products using Alkermes’ nanoparticulate technology. While the move is expected to result in only a modest near-term impact on the Dublin-based firm’s bottom line, it took both company management and investors by surprise.
Tracon Pharmaceuticals Inc. tapped Biocytogen Pharmaceuticals Co. Ltd.’s wholly owned subsidiary, Eucure Biopharma Co. Ltd., for U.S. rights to CTLA4 antibody YH-001, which it plans to use in immunotherapy studies in combination with its PD-L1 inhibitor.
Takeda Pharmaceutical Co. Ltd. and JCR Pharmaceuticals Co. Ltd. have negotiated a geographically-focused licensing deal to develop and commercialize JR-141 (pabinafusp alfa), a potential therapy for mucopolysaccharidosis type II, also known as Hunter syndrome.
Everest Medicines Ltd. has in-licensed a Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of renal diseases from Suzhou Sinovent Pharmaceuticals Co. Ltd. and Sinomab Bioscience Ltd. in a deal worth up to $561 million. Everest gained global rights to develop, produce and commercialize the candidate, XNW-1011.
In a couple of deals worth more than $500 million, Everest Medicines Ltd. is picking up Asian rights to Providence Therapeutics Holdings Inc.’s mRNA candidates, including rights to a mRNA COVID-19 vaccine candidate currently in phase II testing.
RSS
